Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs... Show more
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on SDZXF as a result. In of 20 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 107 cases where SDZXF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Moving Average Convergence Divergence Histogram (MACD) for SDZXF turned negative on June 12, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SDZXF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (62.813). P/E Ratio (0.000) is within average values for comparable stocks, (89.433). SDZXF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.124) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (19.290).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDZXF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
A.I.dvisor indicates that over the last year, SDZXF has been loosely correlated with SDZNY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SDZXF jumps, then SDZNY could also see price increases.
Ticker / NAME | Correlation To SDZXF | 1D Price Change % | ||
---|---|---|---|---|
SDZXF | 100% | N/A | ||
SDZNY - SDZXF | 44% Loosely correlated | -0.68% | ||
BNXTF - SDZXF | 29% Poorly correlated | +14.61% | ||
AGYTF - SDZXF | 20% Poorly correlated | N/A | ||
CBSTF - SDZXF | 6% Poorly correlated | -5.49% | ||
ESAIY - SDZXF | 5% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To SDZXF | 1D Price Change % |
---|---|---|
SDZXF | 100% | N/A |
Pharmaceuticals category (297 stocks) | 13% Poorly correlated | +0.85% |
Pharmaceuticals: Other category (203 stocks) | 9% Poorly correlated | +0.38% |